2.Victoza Prevents kidney Disease in Diabetes

In the placebo-controlled, randomized LEADER trial, treatment with liraglutide (Victoza) lowered the incidence of adverse cardiovascular (CV) outcomes in 9340 patients with longstanding type 2 diabetes, most of whom had known CV disease at baseline (NEJM JW Gen Med Jul 15 2016 and N Engl J Med 2016; 375:311). Now, the researchers report positive renal outcomes as well. At baseline, participants' mean age was 64, mean glycosylated hemoglobin (HbA1c) was 8.7%, and mean estimated glomerular filtration rate (eGFR) was 80 mL/minute/1.73 m2.

During average follow-up of 4 years, incidence of a combined renal endpoint (new-onset persistent macroalbuminuria, doubling of serum creatinine, end-stage renal disease, or renal-related death) was significantly lower with liraglutide than with placebo (5.7% vs. 7.2%). New-onset persistent macroalbuminuria accounted for most of this difference. Among patients whose baseline eGFR was between 30 and 60 mL/minute/1.73 m2, mean eGFR declined less with liraglutide than with placebo (by 2 mL/minute/1.73 m2), but no difference was seen in patients whose baseline eGFRs were outside this range.

Read More

This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter